Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV: A Cohort Study

Study (n=4375) found replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide was associated with adverse metabolic changes, eg weight increase, obesity, worsening lipid levels. Adjusted mean weight increase: 1.7kg vs 0.7kg with continued use of TDF

Annals of Internal Medicine